Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1972 Feb;44(2):386P–387P.

Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.

D G Jones, J A Lenman, M A Robertson, M J Turnbull
PMCID: PMC1666048  PMID: 4668639

Full text

PDF
386P

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther. 1962 Dec;138:360–375. [PubMed] [Google Scholar]
  2. ANTON A. H., SAYRE D. F. THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL. J Pharmacol Exp Ther. 1964 Sep;145:326–336. [PubMed] [Google Scholar]
  3. Brune G. G., Pflughaupt K. W. Effects of L-DOPA treatment on indole metabolism in Parkinson's disease. Experientia. 1971 May 15;27(5):516–516. doi: 10.1007/BF02147571. [DOI] [PubMed] [Google Scholar]
  4. FRAM D. H., GREEN J. P. THE PRESENCE AND MEASUREMENT OF METHYLHISTAMINE IN URINE. J Biol Chem. 1965 May;240:2036–2042. [PubMed] [Google Scholar]
  5. Fieschi C., Nardini M., Casacchia M., Tedone M. E. Amantadine for Parkinson's disease. Lancet. 1970 May 2;1(7653):945–946. doi: 10.1016/s0140-6736(70)91065-2. [DOI] [PubMed] [Google Scholar]
  6. Grelak R. P., Clark R., Stump J. M., Vernier V. G. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science. 1970 Jul 10;169(3941):203–204. doi: 10.1126/science.169.3941.203. [DOI] [PubMed] [Google Scholar]
  7. MACFARLANE P. S., DALGLIESH C. E., DUTTON R. W., LENNOX B., NYHUS L. M., SMITH A. N. Endocrine aspects of argentaffinoma, with special reference to the use of urinary 5-hydroxyindoleacetic acid estimations in diagnosis. Scott Med J. 1956 Apr;1(4):148–155. doi: 10.1177/003693305600100402. [DOI] [PubMed] [Google Scholar]
  8. OATES J. A., MARSH E., SJOERDSMA A. Studies on histamine in human urine using a fluorometric method of assay. Clin Chim Acta. 1962 Jul;7:488–497. doi: 10.1016/0009-8981(62)90089-x. [DOI] [PubMed] [Google Scholar]
  9. Parkes J. D., Zilkha K. J., Marsden P., Baxter R. C., Knill-Jones R. P. Amantadine dosage in treatment of Parkinson's disease. Lancet. 1970 May 30;1(7657):1130–1133. doi: 10.1016/s0140-6736(70)91211-0. [DOI] [PubMed] [Google Scholar]
  10. Sato T. L. The quantitative determination of 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid) in urine. J Lab Clin Med. 1965 Sep;66(3):517–525. [PubMed] [Google Scholar]
  11. Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]
  12. Stromberg U., Svensson T. H., Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. doi: 10.1111/j.2042-7158.1970.tb08487.x. [DOI] [PubMed] [Google Scholar]
  13. White T. Histamine and methylhistamine in cat brain and other tissues. Br J Pharmacol Chemother. 1966 Feb;26(2):494–501. doi: 10.1111/j.1476-5381.1966.tb01930.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES